Brand-Blinding Needed In Comparison Studies, WaterWipes Told In Review Of Baby Wipe Claim

Firm Qualifies '#1 Clinically Proven' Claim After NAD Review On Kimberly-Clark Challenge

NAD says firm's superiority and establishment claims should be removed from marketing. WaterWipes relied on results from “Baby Skin Integrity Comparison Survey” published in Journal of Pediatrics and Neonatology, but NAD agreed with challenger Kimberly-Clark that not blinding the brands from study subjects weakened the results.

• Source: Alamy (Alamy Stock Photo)

WaterWipes Inc.'s study comparing its baby wipes to other brands used on infants until they were 8 weeks old didn't conceal the brand names from participants, a key reason why it wasn't enough to support “#1” and “clinically proven #1” ad claims in an industry self-regulation review.

BBB National Programs Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Marketing & Advertising

Danes Get OTC Access To ED Treatment

 
• By 

Navamedic has launched Eroxon in Danish pharmacies giving men in the country OTC access to an ED treatment for the first time.

Alfasigma Seeking Slice Of EU’s Largest OTC Market With German Launch

 
• By 

Italy's Alfasigma has expanded its operation in Germany with the creation of a new Consumer Healthcare unit. Led by Rüdiger Hoppe, the business is rolling out OTC medical devices and dietary supplements in the gastrointestinal category.

Maxwellia Launches UK TV Campaign For Evana Showing Reality Of Menstruation

 
• By 

Maxwellia's “bold, honest, and completely unfiltered” campaign for Evana menstrual health brand tells the story of a woman dealing with the realities of a heavy period, showing “real blood, real leaks.”

Haleon Launches ‘Prescription Strength’ Hayfever Remedy In The UK

 
• By 

Pirilieve Hayfever Relief Tablets contain 120mg fexofenadine hydrochloride, which the firm notes is an active ingredient that was “previously only available behind pharmacy counters.”

More from Business

Danes Get OTC Access To ED Treatment

 
• By 

Navamedic has launched Eroxon in Danish pharmacies giving men in the country OTC access to an ED treatment for the first time.

Perrigo Sees Growth Opportunities In Tariff Storm

 

As largest provider of private label/store brand OTCs with “100 plus molecules across 100% price point coverage,” CEO Patrick Lockwood-Taylor says Perrigo’s in position to capitalize as consumers become “more cautious” and look for lower-priced products.

Haleon Targets Low Income Households In Push To Reach 1bn More Consumers

 
• By 

Haleon wants to reach one billion more consumers by 2030 and plans to do this by tailoring products to those outside the highest income bracket. The UK-based firm's five-year growth plan will also see it generate £0.8bn in productivity savings.